Immune cells take on tough leukemia in early trial
NCT ID NCT05987696
First seen Feb 14, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This early-phase study tested a new treatment using lab-grown immune cells (NK cells) in 2 adults with acute myeloid leukemia (AML) that had come back or not responded to standard therapy. The main goal was to see if the treatment is safe and tolerable. Researchers also looked for signs that the cells could reduce or clear the leukemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.